Potential role of miR-139-5p in cancer diagnosis, prognosis and therapy (Review)
- Authors:
- Ling‑Li Huang
- Ling‑Wei Huang
- Lei Wang
- Ben‑Ding Tong
- Qing Wei
- Xuan‑Sheng Ding
-
Affiliations: Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China, Key Laboratory for Space Biosciences and Biotechnology, Institute of Special Environmental Biophysics, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shanxi 710072, P.R. China, Department of Pharmacy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210009, P.R. China - Published online on: June 8, 2017 https://doi.org/10.3892/ol.2017.6351
- Pages: 1215-1222
-
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee RC, Feinbaum RL and Ambros V: The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:pp. 15524–15529. 2002; View Article : Google Scholar : PubMed/NCBI | |
|
Saba R, Goodman CD, Huzarewich RL, Robertson C and Booth SA: A miRNA signature of prion induced neurodegeneration. PLoS One. 3:e36522008. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Chen Z, Yu J, Xia J and Zhou X: MicroRNA profiling and head and neck cancer. Comp Funct Genomics. 8375142009.PubMed/NCBI | |
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Leong MH, Harms B, Kennedy G and Chen L: MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol. 19:5615–5621. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q and Liu J: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 84:320–330. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gu W, Li X and Wang J: miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep. 31:397–404. 2014.PubMed/NCBI | |
|
Bar M, Wyman SK, Fritz BR, Qi J, Garg KS, Parkin RK, Kroh EM, Bendoraite A, Mitchell PS, Nelson AM, et al: MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells. 26:2496–2505. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D and Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A and Sculier JP: Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J. 33:352–359. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 101:241–249. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ and Kerin MJ: MicroRNA signature analysis in colorectal cancer: Identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis. 26:1415–1422. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa M: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Chen HC, Chiang CW, Yeh CT, Chen SJ and Chou CK: Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res. 40:10478–10493. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miles GD, Seiler M, Rodriguez L, Rajagopal G and Bhanot G: Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 5:1642012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu Y, Yin L and Kim SJ: Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. PLoS One. 8:e770682013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Liu R, Sheng J, Liao J, Wang Y, Pan E, Guo W, Pu Y and Yin L: Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep. 29:169–176. 2013.PubMed/NCBI | |
|
Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE and Nikiforova MN: MicroRNA profile of poorly differentiated thyroid carcinomas: New diagnostic and prognostic insights. J Mol Endocrinol. 52:181–189. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y, Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al: MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther. 19:477–483. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P and Bechara FG: Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, et al: Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI | |
|
Luo HN, Wang ZH, Sheng Y, Zhang Q, Yan J, Hou J, Zhu K, Cheng Y, Xu YL, Zhang XH, et al: MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells. Med Oncol. 31:7892014. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Hang M, Yuan CY, Wu FL, Chen SB and Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870. 2015.PubMed/NCBI | |
|
Li L, Li B, Chen D, Liu L, Huang C, Lu Z, Lun L and Wan X: miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. Oncol Rep. 34:51–58. 2015.PubMed/NCBI | |
|
Mi L, Chen Y, Zheng X, Li Y, Zhang Q, Mo D and Yang G: MicroRNA-139-5p suppresses 3T3-L1 preadipocyte differentiation through notch and IRS1/PI3K/Akt insulin signaling pathways. J Cell Biochem. 116:1195–1204. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mi L, Li Y, Zhang Q, Zhao C, Peng Y, Yang G and Zheng X: MicroRNA-139-5p regulates C2C12 cell myogenesis through blocking Wnt/β-catenin signaling pathway. Biochem Cell Biol. 93:8–15. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao G, Zhou X, Fang T, Hou Y and Hu Y: Hyaluronic acid promotes the expression of progesterone receptor membrane component 1 via epigenetic silencing of miR-139-5p in human and rat granulosa cells. Biol Reprod. 91:1162014. View Article : Google Scholar : PubMed/NCBI | |
|
MacLellan SA, MacAulay C, Lam S and Garnis C: Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol. 14:272014. View Article : Google Scholar : PubMed/NCBI | |
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:pp. 10513–10518. 2008; View Article : Google Scholar : PubMed/NCBI | |
|
Cava C, Bertoli G, Ripamonti M, Mauri G, Zoppis I, Rosa PA Della, Gilardi MC and Castiglioni I: Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. PLoS One. 9:e976812014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang HD, Jiang LH, Sun DW, Li J and Tang JH: MiR-139-5p: Promising biomarker for cancer. Tumour Biol. 36:1355–1365. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini I, Bisceglia M, Beck-Peccoz P, et al: Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer. 17:135–146. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shen K, Mao R, Ma L, Li Y, Qiu Y, Cui D, Le V, Yin P, Ni L and Liu J: Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer. FEBS J. 281:3609–3624. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tombol Z, Eder K, Kovács A, Szabó PM, Kulka J, Likó I, Zalatnai A, Rácz G, Tóth M, Patócs A, et al: MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol. 23:1583–1595. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Qin C, Huang RY and Wang ZX: Potential role of miR-100 in cancer diagnosis, prognosis, and therapy. Tumour Biol. 36:1403–1409. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gu DN, Huang Q and Tian L: The molecular mechanisms and therapeutic potential of microRNA-7 in cancer. Expert Opin Ther Targets. 19:415–426. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Aghagolzadeh P and Radpour R: New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 22:5678–5693. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS and Ditzel HJ: Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Mol Oncol. 8:874–883. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rask L, Balslev E, Søkilde R, Høgdall E, Flyger H, Eriksen J and Litman T: Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol (Dordr). 37:215–227. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S and Jung K: miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN and Pass HI: microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing. J Thorac Oncol. 8:1156–1162. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Xiong F, Wei X, Yang H and Zhou R: LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 100:2335–2340. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ather MH and Nazim SM: New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. Korean J Urol. 56:553–564. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Guo H, Hu X, Ge S, Qian G and Zhang J: Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. Int J Biochem Cell Biol. 44:1465–1472. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Stork PJ: Does rap1 deserve a bad rap? Trends Biochem Sci. 28:267–275. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S, Ng SS, Chan FK, et al: microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Mol Cancer. 13:1242014. View Article : Google Scholar : PubMed/NCBI | |
|
Mitrea DM, Yoon MK, Ou L and Kriwacki RW: Disorder-function relationships for the cell cycle regulatory proteins p21 and p27. Biol Chem. 393:259–274. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Song M, Yin Y, Zhang J, Zhang B, Bian Z, Quan C, Zhou L, Hu Y, Wang Q, Ni S, et al: MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell. 5:851–861. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S and Weissman AM: The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci USA. 98:pp. 14422–14427. 2001; View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Hou G, Xue L, Li J, Wei P and Xu P: Autocrine motility factor receptor signaling pathway promotes cell invasion via activation of ROCK-2 in esophageal squamous cell cancer cells. Cancer Invest. 28:993–1003. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chiu CG, St-Pierre P, Nabi IR and Wiseman SM: Autocrine motility factor receptor: A clinical review. Expert Rev Anticancer Ther. 8:207–217. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gu J, Chen Y, Huang H, Yin L, Xie Z and Zhang MQ: Gene module based regulator inference identifying miR-139 as a tumor suppressor in colorectal cancer. Mol Biosyst. 10:3249–3254. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO and Wong CM: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 56:622–631. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wong CC, Wong CM, Tung EK, Man K and Ng IO: Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology. 49:1583–1594. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu G, Lin Y, Zhang H and Wu D: miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 463:315–321. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vandewalle C, Van Roy F and Berx G: The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gheldof A, Hulpiau P, van Roy F, De Craene B and Berx G: Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci. 69:2527–2541. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Shen WL, Shi ML, Zhang LZ, Zhang Z, Li P, Xing LY, Luo FY, Sun Q, Zheng XF, et al: Involvement of aberrant miR-139/Jun feedback loop in human gastric cancer. Biochim Biophys Acta. 1853:481–488. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Guo L, Guo Y and Xiao S: Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology. 72:410–416. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon JH, Choi YJ and Lee SG: Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol. 679:24–33. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun X and Liu Y: Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct. 31:319–324. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S and Lees JA: E2f3 is critical for normal cellular proliferation. Gene Dev. 14:690–703. 2000.PubMed/NCBI | |
|
Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A, et al: miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA. 19:1767–1780. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner RT, Xu X, Yi F, Merrill BJ and Cooney AJ: Canonical Wnt/β-catenin regulation of liver receptor homolog-1 mediates pluripotency gene expression. Stem Cells. 28:1794–1804. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Lan F, Huang L, Dong L, Zhu Z, Li Z, Xie Y and Fu J: Suppression of hLRH-1 mediated by a DNA vector-based RNA interference results in cell cycle arrest and induction of apoptosis in hepatocellular carcinoma cell BEL-7402. Biochem Biophys Res Commun. 333:917–924. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chand AL, Herridge KA, Thompson EW and Clyne CD: The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. Endocr Relat Cancer. 17:965–975. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Pure E and Assoian RK: Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol. 176:535–544. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kaneko T, Saito H, Toya M, Satio T, Nakahara K and Hiroi M: Hyaluronic acid inhibits apoptosis in granulosa cells via CD44. J Assist Reprod Genet. 17:162–167. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Peluso JJ, Liu X, Gawkowska A, Lodde V and Wu CA: Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. Mol Cell Endocrinol. 320:153–161. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Szczesna-Skorupa E and Kemper B: Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome p450 reductase. Mol Pharmacol. 79:340–350. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Abe R: Angiogenesis in tumor growth and metastasis. Curr Pharm Des. 14:37792008. View Article : Google Scholar : PubMed/NCBI | |
|
Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y and Sugimachi K: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 128:408–416. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, et al: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 141:2076–2087.e6. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, et al: Invasive breast cancer. J Natl Compr Canc Netw. 5:246–312. 2007.PubMed/NCBI | |
|
Hua W, Sa KD, Zhang X, Jia LT, Zhao J, Yang AG, Zhang R, Fan J and Bian K: MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha. Biochem Biophys Res Commun. 463:1077–1083. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:483–487. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC and Byrd JC: Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol. 21:1466–1471. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM and Byrd JC: Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 13:2144–2150. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kaji D, Miura Y and Takano T: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 366:663–664. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Shi K, Wang Y, Song M, Zhou W, Tu H and Lin Z: Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. Oncotarget. 6:37544–37556. 2015.PubMed/NCBI | |
|
Singh AK, Swarnalatha M and Kumar V: c-ETS1 facilitates G1/S-phase transition by up-regulating cyclin E and CDK2 genes and cooperates with hepatitis B virus X protein for their deregulation. J Biol Chem. 286:21961–21970. 2011. View Article : Google Scholar : PubMed/NCBI |
